BioXcel Therapeutics, Inc. (BTAIQ) Shareholders’ equity 2022–2025
BioXcel Therapeutics, Inc. (BTAIQ) shareholders’ equity at each fiscal year-end, per SEC filings.
-$95.5MFY2025 · since FY2022: $76.8M → -$95.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$95.5M | -2.5% |
| FY2024 | -$93.1M | -64.8% |
| FY2023 | -$56.5M | -173.6% |
| FY2022 | $76.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BTAIQ financial trends
BTAIQ RevenueBTAIQ Net incomeBTAIQ Net marginBTAIQ Gross profitBTAIQ Gross marginBTAIQ Operating incomeBTAIQ Operating marginBTAIQ Operating cash flowBTAIQ Free cash flowBTAIQ Capital expendituresBTAIQ Return on equityBTAIQ Stock buybacksBTAIQ Dividends paidBTAIQ Total assetsBTAIQ Total liabilitiesBTAIQ overview →